Patent: 8,580,264
✉ Email this page to a colleague
Summary for Patent: 8,580,264
Title: | Subcutaneously administered anti-IL-6 receptor antibody |
Abstract: | The present application discloses methods for treating an IL-6-mediated disorder such as rheumatoid arthritis (RA), juvenile idiopathic arthritis (JIA), systemic JIA (sJIA), polyarticular course JIA (pcJIA), systemic sclerosis, or giant cell arteritis (GCA), with subcutaneously administered antibody that binds interleukin-6 receptor (anti-IL-6R antibody). In particular, it relates to identification of a fixed dose of anti-IL-6R antibody, e.g. tocilizumab, which is safe and effective for subcutaneous administration in patients with IL-6-mediated disorders. In addition, formulations and devices useful for subcutaneous administration of an anti-IL-6R antibody are disclosed. |
Inventor(s): | Zhang; Xiaoping (Wayne, NJ), Bao; Min (San Mateo, CA), Jahreis; Angelika M. (Menlo Park, CA), Terao; Kimio (Funabashi, JP) |
Assignee: | Genentech, Inc. (South San Francisco, CA) Hoffmann-La Roche Inc. (Nutley, NJ) |
Application Number: | 13/290,366 |
Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for patent 8,580,264 |
Patent Claims: | see list of patent claims |
Details for Patent 8,580,264
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
---|---|---|---|---|---|---|---|
Genentech, Inc. | RITUXAN | rituximab | Injection | 103705 | 11/26/1997 | ⤷ Try a Trial | 2030-11-08 |
Idec Pharmaceuticals Corp. | RITUXAN | rituximab | Injection | 103737 | 02/19/2002 | ⤷ Try a Trial | 2030-11-08 |
Genentech, Inc. | ACTEMRA | tocilizumab | Injection | 125276 | 01/08/2010 | ⤷ Try a Trial | 2030-11-08 |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |